Supernus Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St

February 27, 2025

Supernus Pharmaceuticals (NASDAQ:SUPN) Full Year 2024 Results

Key Financial Results

Revenue: US$661.8m (up 8.9% from FY 2023).
Net income: US$73.9m (up by US$72.5m from FY 2023).
Profit margin: 11% (up from 0.2% in FY 2023). The increase in margin was primarily driven by higher revenue.
EPS: US$1.34 (up from US$0.024 in FY 2023).

earnings-and-revenue-history — NasdaqGM:SUPN Earnings and Revenue History February 27th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Supernus Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 4.8% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Supernus Pharmaceuticals' balance sheet health.

If you're looking to trade Supernus Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.